glp-1 semaglutide How medications are transforming diabetes and weight loss treatment Trial suggests GLP-1 combo therapy

Observations from LVAD patients also suggest that while many experience normalization of LV chamber geometry, changes in the ECM and the ratio of LV wall thickness to LV wall radius may not return to normal 37

What to expect: The focus shifts from rapid weight loss to sustainable progress

S., Kanter M

At 48 weeks on 12mg: Visceral fat: -42% reduction (more than total weight loss percentage) Liver fat: -50% reduction based on imaging studies Subcutaneous fat: -28% reduction The fact that visceral and liver fat dropped faster than overall weight helps explain retatrutide's metabolic improvements

van der Lee, K

At higher doses, it may be harder to tolerate, but we wont fully understand its long-term safety risks until we have more data